2026-04236NoticeWallet

Genentech Slaps Down Biosimilar Imports: Patents vs. Patients?

Published Date: 3/4/2026

Notice

Summary

The U.S. International Trade Commission got a complaint from Genentech about certain pertuzumab biosimilars being imported and sold in the U.S. They want to stop these products because of patent issues. The Commission is asking the public to share their thoughts on how this might affect everyone, with decisions and possible actions happening soon, including a 60-day review period.

Analyzed Economic Effects

2 provisions identified: 0 benefits, 1 costs, 1 mixed.

Genentech Seeks Import Ban and Orders

Genentech filed a complaint on February 27, 2026 alleging that certain pertuzumab biosimilars are unlawfully imported and sold in the U.S. The company asks the Commission for a limited exclusion order, cease and desist orders, and for a bond to be imposed on the allegedly infringing articles during the 60-day Presidential review period under 19 U.S.C. 1337(j).

Public Comment Window Is Short and Electronic

The Commission invites public comments on public interest issues and requires written submissions to be filed no later than close of business eight calendar days after this notice's publication; complainant may reply within three calendar days. All filings must be made electronically through the Commission's Electronic Document Information System (EDIS), submissions are limited to five (5) pages, and no paper filings will be accepted until further notice (Docket No. 3890).

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
3/4/2026

Department and Agencies

Department
Independent Agency
Agency
International Trade Commission
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in